Search Results (3)

Background: Prostanoid FP receptor agonists (FP agonists) are widely used as first-line therapies for glaucoma but differ in their potential to induce prostaglandin-associated periorbitopathy (PAP), which may affect surgical outcomes. While several studies have reported an association between PAP and trabeculectomy failure, the impact of these agents on tube shunt procedures such as Ahmed glaucoma valve (AGV) implantation is not well established. Methods: We retrospectively analyzed 298 eyes of 221 patients who underwent trabeculectomy (n = 162) or AGV implantation (n = 136) between 2018 and 2023. The eyes were stratified by preoperative FP agonist use into the high-PAP-inducing-potential (bimatoprost or travoprost) and low-PAP-inducing-potential (latanoprost or tafluprost) groups. The primary outcome was the cumulative 2-year surgical survival rate under three intraocular pressure (IOP)-based definitions. Results: In the trabeculectomy group, the high-PAP-potential group had significantly lower 2-year survival rates than the low-PAP-potential group under all definitions. Cox proportional hazards analysis identified use of a high-PAP-potential FP agonist as a significant risk factor for surgical failure. In the AGV group, a difference between groups was seen only under the most lenient definition, with no differences under stricter criteria. Conclusions: The preoperative use of high-PAP-potential FP agonists is associated with poorer outcomes after trabeculectomy. Although the effect on AGV implantation appears limited, it may still influence early postoperative results. These findings underscore the need to consider PAP risk and medication history when selecting surgical procedures for glaucoma. Full article

Introduction: To report the role of prostaglandin-associated periorbitopathy (PAP) severity on the surgical efficacy of Ahmed Glaucoma Valve (AGV) implantation. Subjects and Methods: Retrospective observational case series. Participants were the consecutive 102 eyes from 102 Japanese subjects (55 males, 47 females; mean age ± standard deviation, 74.9 ± 7.8 years) who underwent AGV implantation for primary open-angle glaucoma (POAG), completed full postoperative visits for 12 months, and had information on PAP severity graded by the Shimane University PAP Grading System (SU-PAP). Data were collected via medical chart review. Comparison of surgical success rates among groups stratified by SU-PAP grades (grades 0–3) using survival curve analysis. Failure was defined based on additional glaucoma surgery, IOP reduction in less than 20%, postoperative IOP exceeding 18 mmHg (definition A) or 15 mmHg (definition B), or postoperative visual acuity reduced to no light perception. Results: At 12 months postoperatively, the success rates for grades 0, 1, 2, and 3 were 47%, 43%, 42%, and 73%, respectively, for definition A (p = 0.35) and 35%, 26%, 19%, and 27%, respectively, for definition B (p = 0.64, log-rank test). For definition A, younger age was associated with surgical failure (Hazard ratio = 0.97/year, p = 0.049, Wald test), while no other factors, including gender, preoperative IOP, medications, refractive error, history of conjunctival manipulation procedures, or SU-PAP grade, were associated with surgical failure. For definition B, no factors were found to influence surgical outcomes. Conclusions: The preoperative severity of PAP might not affect the postoperative outcomes of AGV. Given that the success rate of trabeculectomy is influenced by PAP severity, in cases with severe PAP, physicians are advised to consider long-tube shunt surgery as an initial filtration procedure or as a rescue procedure when filtration surgery is unsuccessful. Full article

Background/Objectives: This study aims to evaluate the computed tomography (CT) scans of glaucoma patients using prostaglandin analogs (PGA) in one eye, investigate findings associated with prostaglandin-associated periorbitopathy (PAP), and compare these findings with those of the contralateral eyes. Methods: Patients with open-angle glaucoma who had CT images of the orbital region taken for another reason at least one month after starting PGA treatment in one eye were included in the study. Enophthalmos measurements from thin-slice CT images, along with 3D volume measurements of orbital fat tissue, periorbital muscles, and the optic nerve, were performed. Ophthalmological examination findings and treatment information were collected. The values were compared with those of the contralateral eyes of the same patients not using PGA. Intraclass correlation coefficients (ICCs) were computed to evaluate measurement repeatability. Results: Forty patients were included in the study. Among them, 29 (72.5%) used latanoprost, 9 (22.5%) used bimatoprost, and 2 (5%) used travoprost. The mean enophthalmos values on the treated side (15.5 ± 2.0 mm) were lower than on the untreated side (16.1 ± 1.4 mm), but this difference was not statistically significant (p = 0.07). In 29 patients (72.5%), enophthalmos measurements were smaller on the treated side, with 7 patients (17.5%) showing a difference of 2 mm or more. No significant correlation was found between the duration of PGA use and enophthalmos measurements (p = 0.768 r = −0.048). Additionally, no significant differences were found in orbital fat volume, total extraocular muscle volume, and optic nerve volume (p > 0.05). ICC values demonstrated excellent reliability (ICC > 0.75) for all measurements. Conclusions: We did not find significant differences in enophthalmos measurements, orbital fat volume, total muscle volume, and optic nerve volume between the PGA-treated and untreated eyes. Full article